Four pharmaceutical companies, Kenilworth, NJ-based Schering-Plough Corp; The Procter and Gamble Co., Cincinnati; Eli Lilly and Co., Indianapolis; and Abbott Laboratories, Abbott Park, IL, were named to Fortune magazine's list of "50 Best Companies for Minorities." The list was published in the July 9 issue of the magazine.
Four pharmaceutical companies, Kenilworth, NJ-based Schering-Plough Corp; The Procter and Gamble Co., Cincinnati; Eli Lilly and Co., Indianapolis; and Abbott Laboratories, Abbott Park, IL, were named to Fortune magazine's list of "50 Best Companies for Minorities." The list was published in the July 9 issue of the magazine.
To compile the ranking, Fortune, in conjunction with the nonprofit Center for Responsibility in Business, surveyed all Fortune 1,000 companies and the 200 largest privately held firms. Companies were judged on their overall diversity programs, numbers of minority workers, employees having career goals related to minorities, numbers of future minority management candidates, implementation of a formal mentoring program for minorities, level of purchasing from minority-owned firms, and charitable contributions for programs or organizations that primarily benefit minorities.
"Fostering a diverse and inclusive workplace is essential for Abbott's success," said Miles D. White, chairman and chief executive officer of Abbott Laboratories, which appears on the list for the fourth consecutive year. "Embracing diversity cultivates an innovative and inspiring environment for our employees and our business."
The survey also compared each company's overall turnover rate with that of non-minorities and assessed how well minorities are represented in management versus the total work force.
"A commitment to work force diversity is an important responsibility of every manager at Schering-Plough," said John P. Ryan, senior vice president, human resources of Schering-Plough. "This commitment encompasses not only our recruiting efforts, but also our ongoing efforts to challenge employees of both genders and all nationalities and races to achieve their full potential through career development and job opportunities." PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.